RNA, U6atac small nuclear 35, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC35P profile across patient tissues and cancer cell-line models. RNU6ATAC35P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC35P is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RNU6ATAC35P RNA expression shows 13,235 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, THCA, and TGCT as cancer lineages where RNU6ATAC35P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC35P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC35P survival associations across molecular data types. RNU6ATAC35P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC35P RNA expression–survival associations across cancer types. High RNU6ATAC35P expression shows unfavorable associations in DLBC and ESCA, but favorable associations in KIRC, LGG, UCEC and PAAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for RNU6ATAC35P RNA expression.
This table summarizes RNU6ATAC35P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC35P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC35P shows lower tumor expression in THCA, LUAD, COAD, BRCA, KICH and LUSC. The THCA box plot shows higher RNU6ATAC35P RNA expression in normal versus tumor tissue (log2 FC = −1.638, t-test p < 0.001).
This table shows molecular features associated with RNU6ATAC35P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC35P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
